By Colin Kellaher

 

Emergent BioSolutions Inc. on Friday said the Food and Drug Administration accepted for review its application seeking approval of its anthrax vaccine candidate AV7909.

The Gaithersburg, Md., maker of vaccines and therapeutics, which has spent two decades working with the U.S. government on its anthrax program, is studying the vaccine for post-exposure prevention of disease following suspected or confirmed exposure in people ages 18 through 65 when administered in conjunction with recommended antibacterial drugs.

Emergent said the FDA set a target action date for a decision in April 2023.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 24, 2022 06:58 ET (10:58 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Emergent Biosolutions Charts.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Emergent Biosolutions Charts.